Extreme Networks And 2 Additional Stocks Estimated To Be Trading Below Their Fair Value

In the last week, the United States market has stayed flat, yet it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that are potentially undervalued can present opportunities for investors looking to capitalize on discrepancies between stock prices and their intrinsic values.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name Current Price Fair Value (Est) Discount (Est) Seagate Technology Holdings (STX) $673.64 $1330.31 49.4% Q2 Holdings (QTWO) $50.75 $97.97 48.2% First Merchants (FRME) $40.44 $77.39 47.7% FinWise Bancorp (FINW) $15.55 $29.71 47.7% FB Financial (FBK) $54.07 $103.19 47.6% Chemung Financial (CHMG) $66.41 $127.22 47.8% BillionToOne (BLLN) $75.05 $147.13 49% AppLovin (APP) $446.35 $858.66 48% Alnylam Pharmaceuticals (ALNY) $309.49 $610.25 49.3% Aldeyra Therapeutics (ALDX) $1.52 $3.02 49.6%

Click here to see the full list of 150 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's uncover some gems from our specialized screener.

Extreme Networks

Overview: Extreme Networks, Inc. is a company that develops, markets, and sells network infrastructure equipment and related software globally, with a market cap of approximately $2.93 billion.

Operations: Revenue Segments (in millions of $): Extreme Networks generates its revenue through the sale of network infrastructure equipment and associated software across various regions including the Americas, Europe, the Middle East, Africa, and Asia-Pacific.

Estimated Discount To Fair Value: 35%

Extreme Networks is trading at 35% below its estimated fair value, with shares priced at US$22.09 against a future cash flow valuation of US$33.97. Recent earnings showed strong growth, with net income rising to US$10.59 million in Q3 from US$3.46 million a year ago, driven by increased revenue and strategic product innovations like Extreme Platform ONE. The company forecasts robust earnings growth of 27.1% annually over the next three years, outpacing the broader market expectations.

The growth report we've compiled suggests that Extreme Networks' future prospects could be on the up. Take a closer look at Extreme Networks' balance sheet health here in our report.EXTR Discounted Cash Flow as at May 2026

FTAI Aviation

Overview: FTAI Aviation Ltd. owns, acquires, and sells aviation equipment for global transportation of goods and people, with a market cap of $21.86 billion.

Operations: FTAI Aviation generates revenue through the ownership, acquisition, and sale of aviation equipment used in worldwide transportation.

Estimated Discount To Fair Value: 18.7%

FTAI Aviation is trading at US$249.67, about 18.7% below its estimated fair value of US$307.22 based on discounted cash flow analysis. Despite a decline in sales to US$39.89 million, revenue surged to US$830.7 million in Q1 2026 from the previous year, boosting net income to US$137.9 million. Earnings are projected to grow significantly at 28% annually, surpassing market averages and highlighting strong future cash flow potential despite current debt challenges.

Story Continues

Our growth report here indicates FTAI Aviation may be poised for an improving outlook. Dive into the specifics of FTAI Aviation here with our thorough financial health report.FTAI Discounted Cash Flow as at May 2026

Natera

Overview: Natera, Inc. is a diagnostics company that develops and commercializes molecular testing services globally, with a market cap of $27.81 billion.

Operations: The company generates revenue of $2.31 billion from its molecular testing services offered on a global scale.

Estimated Discount To Fair Value: 32.4%

Natera is trading at US$206.16, significantly below its estimated future cash flow value of US$305.04, indicating potential undervaluation based on discounted cash flow analysis. Recent revenue growth to US$2.31 billion and a forecasted annual profit increase of 54.57% suggest robust financial health despite current net losses. The company’s advancements in genomic testing, such as the Prospera test for transplants and Signatera for cancer monitoring, further bolster its long-term growth prospects amidst ongoing legal challenges.

According our earnings growth report, there's an indication that Natera might be ready to expand. Click here and access our complete balance sheet health report to understand the dynamics of Natera.NTRA Discounted Cash Flow as at May 2026

Summing It All Up

Discover the full array of 150 Undervalued US Stocks Based On Cash Flows right here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Curious About Other Options?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include EXTRFTAI and NTRA.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments